-
The authors conclude that in a population-based cohort undergoing 4 years of follow-up, the prevalence of diastolic dysfunction increased and that diastolic dysfunction was associated with development of heart failure during 6 years of subsequent follow-up.
-
It has been customary to ask patients on warfarin, once controlled and stable, to return on a monthly basis for recheck.
-
-
It took polymerase chain reaction at least 30 years (by my reckoning) to evolve from its inception as a promising method for laboratory detection of infectious agents in patient samples to its widespread utilization in diagnostic clinical microbiology laboratories.
-
Unless you were bent on becoming a forensic entomologist as a kid, there is nothing worse than pulling back a bed sheet and finding ... maggots. Every so many years, I find an ICU patient, typically sedated and intubated, with fly larvae crawling out of some orifice or wound.
-
Clostridium difficile infection (CDI) is a serious medical condition associated with significant morbidity and mortality. Thirty-day mortality rates associated with CDI have been estimated to be anywhere from 6.0% to 32.5%, with higher mortality rates observed in older patients.
-
A total of 1,763 HIV-1 serodiscordant couples in nine countries with the infected partner having CD4+ counts of 350-500/mL were randomized 1:1 to early (immediate) vs. delayed (CD4+ had declined to ¡Ü 250/mL or after development of an AIDS-related illness) antiretroviral therapy of the infected partner.
-
Herrera and colleagues reviewed the use of interferon-ã release assays (IGRAs) for the diagnosis of latent tuberculosis infection (LTBI).
-
The association of HPV infection and bladder cancer has been a topic of discussion for the last decade, but has not surfaced because of important other outcomes of HPV infection. HPV is increasing in its prevalence globally and its chronic nature raises many issues in and around the genital tract.
-
In this issue: ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions.
